Related Experiment Video
Updated: Apr 16, 2026
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Intraoperative radiotherapy in early breast cancer
E Esposito1, B Anninga, S Harris
1Research Oncology, Division of Cancer Studies, King's College London, Guy's Hospital, London, UK; Department of Breast Surgery, Istituto Nazionale per lo Studio e la cura dei tumori 'Fondazione Giovanni Pascale' - IRCCS, Naples, Italy.
Intraoperative radiotherapy (IORT) offers a single-dose radiation treatment during surgery, potentially reducing toxicity compared to traditional external beam radiotherapy (EBRT). While local recurrence rates were slightly higher in trials, IORT remains a viable alternative for selected breast cancer patients.
Area of Science:
- Oncology
- Radiation Oncology
- Surgical Oncology
Background:
- Intraoperative radiotherapy (IORT) presents a novel approach to breast cancer treatment, contrasting with conventional multi-week external beam radiotherapy (EBRT).
- IORT delivers radiation during tumor excision, targeting the primary site of recurrence risk while sparing healthy tissue.
- The rationale stems from over 90% of local recurrences occurring near the initial surgical site.
Purpose of the Study:
- To review and analyze various techniques and devices used in intraoperative radiotherapy (IORT) trials.
- To evaluate the efficacy and safety of IORT as an alternative to conventional radiotherapy for breast cancer.
Main Methods:
- Systematic review of published randomized clinical trials on IORT techniques.
- Analysis of data from the TARGIT-A and ELIOT trials comparing IORT with EBRT.
Main Results:
- IORT provides a single-fraction radiation option at the time of surgery, reducing overall treatment time.
- While IORT showed slightly higher local recurrence rates than EBRT in the TARGIT-A and ELIOT trials, these rates remained within acceptable non-inferiority and equivalence margins.
- IORT demonstrated reduced toxicity and other potential benefits compared to EBRT.
Conclusions:
- Further long-term follow-up, patient selection refinement, and cost-effectiveness studies are necessary for IORT.
- IORT can be considered a valid alternative to EBRT for select breast cancer patients under established protocols.
- Monitoring outcomes in national registries is recommended for ongoing evaluation of IORT effectiveness.
